| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 274.69M | 266.76M | 256.13M | 232.02M | 205.45M | 170.45M |
| Gross Profit | 155.07M | 150.82M | 145.13M | 128.77M | 118.17M | 94.00M |
| EBITDA | 30.17M | 31.24M | 30.09M | 23.44M | 36.72M | 13.75M |
| Net Income | 4.75M | 13.44M | 6.72M | -2.12M | 13.15M | -7.04M |
Balance Sheet | ||||||
| Total Assets | 415.51M | 396.34M | 396.63M | 411.26M | 413.41M | 398.78M |
| Cash, Cash Equivalents and Short-Term Investments | 132.02M | 102.30M | 127.57M | 140.87M | 196.03M | 136.47M |
| Total Debt | 64.28M | 41.28M | 64.40M | 80.98M | 99.11M | 140.84M |
| Total Liabilities | 164.14M | 147.84M | 160.04M | 182.33M | 180.83M | 235.83M |
| Stockholders Equity | 251.45M | 248.58M | 236.65M | 228.96M | 232.58M | 162.96M |
Cash Flow | ||||||
| Free Cash Flow | 6.65M | 5.08M | 8.40M | -2.48M | 14.12M | 12.33M |
| Operating Cash Flow | 26.26M | 31.46M | 20.16M | 22.29M | 25.84M | 29.98M |
| Investing Cash Flow | -16.47M | -28.59M | -11.04M | -53.86M | -13.13M | -28.27M |
| Financing Cash Flow | 6.99M | -27.64M | -22.37M | -22.51M | 71.16M | -16.89M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $255.12M | 39.10 | 14.60% | 0.53% | 11.05% | 18.55% | |
67 Neutral | $355.58M | 72.01 | 1.73% | ― | 0.73% | -54.49% | |
66 Neutral | $253.58M | 1.52 | ― | 13.13% | -19.17% | 308.81% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
56 Neutral | $309.52M | 74.90 | 0.84% | ― | 1.71% | ― | |
48 Neutral | $357.56M | ― | -37.23% | ― | 2.97% | 53.53% | |
48 Neutral | $173.94M | ― | -120.79% | ― | -9.86% | 0.87% |
On November 14, 2025, Materialise NV held an Extraordinary Shareholders’ Meeting where all proposed resolutions were approved. These resolutions included share capital movements, a new authorization for share buybacks, amendments to the articles of association, and the introduction of double voting rights for certain shares. Additionally, the remuneration policy was approved, the statutory auditor was mandated with sustainability assurance, and the board of directors’ composition was confirmed. These changes are set to enhance Materialise’s corporate governance and strategic flexibility, potentially impacting its market positioning positively.
On October 30, 2025, Materialise NV announced plans to pursue an additional listing of its ordinary shares on Euronext Brussels to complement its existing Nasdaq listing. This move is intended to broaden its investor base and enhance its profile among European investors, reflecting the company’s commitment to global growth. Additionally, the company plans an up to EUR 30 million ADS buyback program over Nasdaq, which is contingent upon shareholder approval and the completion of the Euronext listing. The extraordinary general shareholders’ meeting scheduled for November 14, 2025, will address these proposals, among other governance and operational matters. The listing on Euronext Brussels is expected to occur around November 20, 2025, and aims to provide Materialise with enhanced operational flexibility and potential access to additional capital in the future.
On October 28, 2025, Materialise NV reported its financial results for the third quarter of 2025, highlighting a 2.2% increase in total consolidated revenue compared to the previous quarter, though a 3.5% decrease from the same period in 2024. The Materialise Medical segment achieved a record quarterly revenue growth of 10.3% year-over-year, despite macroeconomic challenges impacting overall revenue, particularly in the Manufacturing segment. The company maintained strong cash flow and a positive net result, with a net profit of 1,848 kEUR. CEO Brigitte de Vet-Veithen emphasized the company’s focus on cost control and continued R&D investments to ensure future growth, while acknowledging ongoing geopolitical and economic uncertainties.
Materialise NV reported a decrease in total revenue by 3.5% for the third quarter of 2025 compared to the same period in 2024, with a notable increase in their Medical segment revenue by 10.3%. Despite the revenue decline, the company saw an increase in cash flow from operating activities and a stronger net cash position. However, the operating result and net profit both decreased compared to the previous year, reflecting challenges in their Software and Manufacturing segments. The company’s strategic focus on the Medical segment is evident with increased R&D investments, which may influence future growth in this area.